VTv Therapeutics Total Stockholder Equity Over Time
| VTVT Stock | USD 15.51 0.09 0.58% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out VTv Therapeutics Performance and VTv Therapeutics Correlation. VTv |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VTv Therapeutics. If investors know VTv will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VTv Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.37) | Revenue Per Share 0.411 | Return On Assets (0.41) | Return On Equity (3.62) |
The market value of vTv Therapeutics is measured differently than its book value, which is the value of VTv that is recorded on the company's balance sheet. Investors also form their own opinion of VTv Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VTv Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VTv Therapeutics' market value can be influenced by many factors that don't directly affect VTv Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VTv Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VTv Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VTv Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Stockholder Equity Analysis
Compare vTv Therapeutics and related stocks such as Zura Bio Limited, Apexigen, and Phio Pharmaceuticals Corp Total Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | (32.1 M) | 59.3 M | 62.3 M |
| PHIO | (587 K) | (587 K) | (5.8 M) | 4.9 M | 2.7 M | 8.9 M | 10.9 M | 1.8 M | 13.6 M | 5.7 M | 13 M | 21.9 M | 10.8 M | 7.7 M | 8.1 M |
| IMMX | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (4.7 M) | 18 M | 13.2 M | 16.4 M | 8.6 M |
| NBY | 802 K | 9.3 M | 14 M | 8.5 M | 1.8 M | (5.1 M) | 7.1 M | 2.6 M | 5 M | 973 K | 12.3 M | 10.2 M | 10.6 M | 3.3 M | 5.3 M |
| INM | 4.2 M | 2.7 K | (44.1 K) | 1.5 M | 1.3 M | 760.6 K | 6.1 M | 20.6 M | 13.9 M | 5.6 M | 7.4 M | 9.1 M | 12.1 M | 9.2 M | 9.7 M |
| GOVX | 3.1 M | 703.6 K | 1.2 M | 2.5 M | 1.1 M | 1.2 M | 240.4 K | (321.1 K) | (1 M) | (1.6 M) | 9.6 M | 4.4 M | 26.6 M | 5.8 M | 2.9 M |
| GBIO | (41.6 M) | (41.6 M) | (41.6 M) | (41.6 M) | (41.6 M) | (41.6 M) | (41.6 M) | (41.6 M) | (41.6 M) | (98.6 M) | 268 M | 381.7 M | 282.5 M | 203.1 M | 182.5 M |
| KRON | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (23.2 M) | 465.5 M | 345.1 M | 244.5 M | 159.1 M | 217 M |
| ERAS | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (114 M) | (238.2 M) | (481 M) | 316.7 M | 332.5 M |
| CCCC | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (112 M) | 280.8 M | 389.6 M | 289.2 M | 246.1 M | 185.9 M |
| EWTX | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (33.4 M) | 274.4 M | 346.7 M | 318.8 M | 195.7 M |
| ALLR | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 26.9 M | 18.8 M | 1.9 M | (2.8 M) | (2.6 M) |
| NRBO | (531 K) | (531 K) | (531 K) | (531 K) | (531 K) | (12.4 M) | 20.6 M | 3.9 M | (76.3 M) | 12.3 M | 7.2 M | 14.6 M | 21.8 M | 16.7 M | 17.5 M |
| VRAX | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (596.2 K) | (974.6 K) | 9.1 M | 5.4 M | 5.6 M |
| QNRX | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 28.5 M | 18.9 M | 4.3 M | (6.6 M) | 657 K | 7.4 M | 5.7 M | 6.6 M |
| PYXS | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (15.6 M) | 261.3 M | 160.8 M | 125.7 M | 116.5 M |
| CYTO | 472.6 K | 472.6 K | (244 K) | 9 M | 53.3 M | 44.7 M | 14.1 M | (2.2 M) | 3.6 M | 6 M | 16.8 M | 12.7 M | (8.3 M) | 6.5 M | 9.6 M |
| ELEV | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (23.1 M) | 140.7 M | 49 M | 54.8 M | 47.4 M |
vTv Therapeutics and related stocks such as Zura Bio Limited, Apexigen, and Phio Pharmaceuticals Corp Total Stockholder Equity description
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.My Equities
My Current Equities and Potential Positions
| vTv Therapeutics | VTVT |
| Classification | Pharmaceutical Products |
| Location | North Carolina; U.S.A |
| Exchange | NASDAQ Exchange |
USD 15.51
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.